A Phase 3 interventional study of Obeticholic acid (10 mg) and Obeticholic acid (10 mg to 25 mg) in Compensated Cirrhosis and Nonalcoholic Steatohepatitis, sponsored by Intercept Pharmaceuticals. Completed at 192 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Intercept Pharmaceuticals (part of Alfasigma S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 17th largest by enrollment of the 460 interventional ones that give a count, is one of 26 that started in 2017, is one of 29 in phase 3, and was the 230th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 26 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 919 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
This study is registered under Intercept Pharmaceuticals, one of the names counted as Alfasigma S.p.A.. Under that name alone:
Intercept Pharmaceuticals is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Alfasigma S.p.A. has 4 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg OCA for up to 18 months
Drug: Obeticholic acid (10 mg)
10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
Drug: Obeticholic acid (10 mg to 25 mg)
Placebo for up to 18 months
Drug: Placebo
Tablets administered orally once daily.
Also known as: OCA, 6alpha-ethylchenodeoxycholic acid (6-ECDCA), INT-747
Tablets administered orally once daily.
Also known as: OCA, 6alpha-ethylchenodeoxycholic acid (6-ECDCA), INT-747
Tablets administered orally once daily.
DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)
Fibrosis stage was evaluated by NASH Clinical Research Network(CRN)Fibrosis Staging System with stages:0=no fibrosis;1=perisinusoidal/periportal;1A=mild,zone 3,perisinusoidal;1B=moderate,zone 3,perisinusoidal;1C=portal/periportal;2=perisinusoidal and portal/periportal;3=bridging fibrosis;4=cirrhosis.No worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade as per scoring in relevant nonalcoholic fatty liver disease activity score (NAS) categories.NAS is semiquantitative scoring system based on unweighted sum of:steatosis (0=\<5% to 3=\>66%),lobular inflammation(0=no foci to 3=\>4 foci/200x),hepatocellular ballooning(0=none to 2=many cells/prominent ballooning)scores.Total scale range:0-12;0:no features of fatty liver disease and 12:highest degree of fatty liver disease.Higher scores:worse symptoms.Responders:did not discontinue treatment due to Adverse event(AE) or did not die and had evaluable post-Baseline biopsy assessment
Time frame: Up to 18 months
OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
Time frame: Up to 12 months
OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)
Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled transient elastography (TE) method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. Baseline was defined as the last value collected prior to the first administration of the investigational product (IP). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to Month 12
OLE Phase: Fibrosis-4 (FIB-4) at Baseline
FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, alanine aminotransferase (ALT) and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, Aspartate aminotransferase (AST) and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[Units per Liter {U/L}\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.
Time frame: Baseline (Day 1)
OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline
ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised hyaluronic acid (HA), tissue inhibitor of metalloproteinase (TIMP1) and procollagen III N-terminal peptide (PIIINP). Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.
Time frame: Baseline (Day 1)
OLE Phase: Number of Participants Reporting All-cause Mortality
All-cause mortality is defined as death due to any cause. Number of participants reporting all-cause mortality is presented
Time frame: Up to Month 12
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related Death
Adjudication was performed under the review of Hepatic Safety Adjudication Committee (HSAC) of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for the following is presented: Ascites (secondary to cirrhosis and requiring medical intervention), Hepatocellular carcinoma (HCC) and non-liver related death.
Time frame: Up to 12 months
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score
The Child-Pugh classification was a scoring system used for the classification of the severity of cirrhosis. It included three continuous variables (bilirubin, albumin, and international normalized ratio) and two discrete variables (ascites and encephalopathy). Each variable was scored 1-3 with 3 indicating most severe derangement. The determination of Child-Pugh score ranged from 5 to 15. The higher the score, the sicker the participant. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for worsening of Child-Pugh score is presented.
Time frame: Up to 12 months
OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15
MELD was a scoring system for assessing the severity of chronic liver disease and to assess prognosis and suitability for liver transplantation. It uses the participant's values for total bilirubin, serum creatinine, and the international normalized ratio for prothrombin time to predict survival. MELD score ranges from 6 (less ill) to 40 (gravely ill) with scores and mortality probability being: Score 40=71.3% mortality; Scores 30-39=52.6% mortality; Scores 20-29=19.6% mortality; Scores10-19=6.0% mortality; Score 9 or less=1.9% mortality. Higher scores indicated greater disease severity. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for MELD score ≥15 is presented.
Time frame: Up to 12 months
DB Phase: Change From Baseline to Month 18 in LSM
Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled TE method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. The principal comparison was at Month 18. Baseline was defined as the last value collected prior to the first administration of the IP. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
Time frame: Baseline and up to Month 18
DB Phase: FIB-4 at Baseline
FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, ALT and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, AST and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.
Time frame: Baseline (Day 1)
DB Phase: ELF at Baseline
ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised HA, TIMP1 and PIIINP. Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.
Time frame: Baseline (Day 1)
The study was conducted at a total of around 286 centers.
| Milestone | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|---|---|---|
| Started | 313 | 296 | 310 | 0 | 0 | 0 |
| Completed | 284 | 274 | 275 | 0 | 0 | 0 |
| Not completed | 29 | 22 | 35 | 0 | 0 | 0 |
| Withdrew: Adverse event | 11 | 12 | 15 | 0 | 0 | 0 |
| Withdrew: Covid-19 non adverse event (ae) related issues | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 5 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant moved to kansas | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site cover and participant was not willing to be transferred | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Stopped investigational product (ip) due to an ae in australia | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Drug holiday | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Spouse underwent surgery and participant was unable to take ip regularly | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Site closure | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 6 | 9 | 0 | 0 | 0 |
| Milestone | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 231 | 221 | 207 |
| Completed | 0 | 0 | 0 | 215 | 208 | 192 |
| Not completed | 0 | 0 | 0 | 16 | 13 | 15 |
| Withdrew: Adverse event | 0 | 0 | 0 | 8 | 5 | 7 |
| Withdrew: Bariatric surgery | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Covid-19 non-ae related issues | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Increase cr from baseline | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Medical reasons by sponsor | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 | 3 | 5 |
Fibrosis stage was evaluated by NASH Clinical Research Network(CRN)Fibrosis Staging System with stages:0=no fibrosis;1=perisinusoidal/periportal;1A=mild,zone 3,perisinusoidal;1B=moderate,zone 3,perisinusoidal;1C=portal/periportal;2=perisinusoidal and portal/periportal;3=bridging fibrosis;4=cirrhosis.No worsening of steatohepatitis was defined as no worsening of lobular inflammation or hepatocellular ballooning grade as per scoring in relevant nonalcoholic fatty liver disease activity score (NAS) categories.NAS is semiquantitative scoring system based on unweighted sum of:steatosis (0=\<5% to 3=\>66%),lobular inflammation(0=no foci to 3=\>4 foci/200x),hepatocellular ballooning(0=none to 2=many cells/prominent ballooning)scores.Total scale range:0-12;0:no features of fatty liver disease and 12:highest degree of fatty liver disease.Higher scores:worse symptoms.Responders:did not discontinue treatment due to Adverse event(AE) or did not die and had evaluable post-Baseline biopsy assessment
| Participants | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg |
|---|---|---|---|
| DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH) | 31 | 33 | 37 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
| Participants | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| AEs | 199 | 213 | 197 |
| SAEs | 26 | 50 | 48 |
Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled transient elastography (TE) method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. Baseline was defined as the last value collected prior to the first administration of the investigational product (IP). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Kilopascal (kPa) | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM) | -2.10 (-7.40 to 3.40) | -2.90 (-7.75 to 1.35) | -3.45 (-7.85 to 0.75) |
FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, alanine aminotransferase (ALT) and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, Aspartate aminotransferase (AST) and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[Units per Liter {U/L}\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.
| Ratio | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| OLE Phase: Fibrosis-4 (FIB-4) at Baseline | 2.179 ± 1.0342 | 2.267 ± 0.9567 | 2.266 ± 1.0867 |
ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised hyaluronic acid (HA), tissue inhibitor of metalloproteinase (TIMP1) and procollagen III N-terminal peptide (PIIINP). Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.
| Scores on a scale | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| OLE Phase: Enhanced Liver Fibrosis (ELF) at Baseline | 10.46 ± 0.933 | 10.50 ± 0.940 | 10.48 ± 0.821 |
All-cause mortality is defined as death due to any cause. Number of participants reporting all-cause mortality is presented
| Participants | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| OLE Phase: Number of Participants Reporting All-cause Mortality | 1 | 0 | 1 |
Non-invasive radiological methods to assess liver stiffness were conducted at selected study sites where the respective devices were available. These assessments were taken by vibration controlled TE method using FibroScan®. Participant was included as a random effect and an unstructured covariance matrix was used assuming convergence could be attained. The principal comparison was at Month 18. Baseline was defined as the last value collected prior to the first administration of the IP. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.
| Kilopascal (kPa) | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg |
|---|---|---|---|
| DB Phase: Change From Baseline to Month 18 in LSM | -0.50 (-5.20 to 5.60) | -3.10 (-7.30 to 3.20) | -2.90 (-8.10 to 2.50) |
FIB-4 was a noninvasive assessment of liver disease assessed by a combination of age, ALT and platelet results. FIB-4 was the ratio of age in years and aminotransferase to platelet count. It was a non-invasive hepatic fibrosis index score combining standard biochemical values, platelets, ALT, AST and age that was calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \<1.45 indicated no or moderate fibrosis and an index of \> 3.25 indicated extensive fibrosis/cirrhosis. Higher ratio indicated worse condition. Baseline was defined as the last value collected prior to the first administration of the IP.
| Ratio | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg |
|---|---|---|---|
| DB Phase: FIB-4 at Baseline | 2.279 ± 1.1091 | 2.475 ± 1.9307 | 2.405 ± 1.1630 |
ELF was non-invasive panel of circulating fibrosis markers calculated from serum biomarkers. The markers of fibrosis comprised HA, TIMP1 and PIIINP. Each of these markers was measured by an immunoassay and an ELF score was generated, from which a level of fibrosis severity could be determined. The ELF test was a composite score: \< 7.7: no to mild fibrosis; ≥ 7.7 - \< 9.8: Moderate fibrosis; ≥ 9.8 - \< 11.3: Severe fibrosis; ≥ 11.3: Cirrhosis.; higher ELF scores were associated with worsening liver fibrosis. Baseline was defined as the last value collected prior to the first administration of the IP.
| Scores on a scale | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg |
|---|---|---|---|
| DB Phase: ELF at Baseline | 10.50 ± 0.921 | 10.60 ± 0.920 | 10.61 ± 0.867 |
Adjudication was performed under the review of Hepatic Safety Adjudication Committee (HSAC) of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for the following is presented: Ascites (secondary to cirrhosis and requiring medical intervention), Hepatocellular carcinoma (HCC) and non-liver related death.
| Participants | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| Ascites (secondary to cirrhosis and requiring medical intervention) | 1 | 0 | 2 |
| HCC | 3 | 1 | 1 |
| Non-liver related death | 1 | 0 | 1 |
The Child-Pugh classification was a scoring system used for the classification of the severity of cirrhosis. It included three continuous variables (bilirubin, albumin, and international normalized ratio) and two discrete variables (ascites and encephalopathy). Each variable was scored 1-3 with 3 indicating most severe derangement. The determination of Child-Pugh score ranged from 5 to 15. The higher the score, the sicker the participant. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for worsening of Child-Pugh score is presented.
| Participants | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh Score | 0 | 1 | 2 |
MELD was a scoring system for assessing the severity of chronic liver disease and to assess prognosis and suitability for liver transplantation. It uses the participant's values for total bilirubin, serum creatinine, and the international normalized ratio for prothrombin time to predict survival. MELD score ranges from 6 (less ill) to 40 (gravely ill) with scores and mortality probability being: Score 40=71.3% mortality; Scores 30-39=52.6% mortality; Scores 20-29=19.6% mortality; Scores10-19=6.0% mortality; Score 9 or less=1.9% mortality. Higher scores indicated greater disease severity. Adjudication was performed under the review of HSAC of all available data for each identified participant to determine liver injury status. Number of participants with adjudicated liver related clinical outcomes for MELD score ≥15 is presented.
| Participants | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|
| OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15 | 0 | 0 | 1 |
Collected over Up to 18 months for DB phase and Up to 1 year for OLE phase. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB: Placebo | 4/312 (1.3%) | 43/312 (13.8%) | 290/312 (92.9%) |
| DB: OCA 10 Milligrams (mg) | 3/295 (1%) | 49/295 (16.6%) | 276/295 (93.6%) |
| DB: OCA 10 mg Titrated to OCA 25 mg | 3/309 (1%) | 46/309 (14.9%) | 291/309 (94.2%) |
| OLE: OCA 10 mg (DB Placebo) | 1/231 (0.4%) | 26/231 (11.3%) | 199/231 (86.1%) |
| OLE: OCA 10 mg (DB OCA 10 mg) | 0/221 (0%) | 50/221 (22.6%) | 213/221 (96.4%) |
| OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) | 1/207 (0.5%) | 48/207 (23.2%) | 197/207 (95.2%) |
| Event | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|---|---|---|
| BradycardiaCardiac disorders | 0/312 | 0/295 | 0/309 | 2/231 | 6/221 | 8/207 |
| COVID-19 pneumoniaInfections and infestations | 0/312 | 2/295 | 3/309 | 3/231 | 2/221 | 7/207 |
| Procedural painInjury, poisoning and procedural complications | 1/312 | 0/295 | 3/309 | 0/231 | 0/221 | 4/207 |
| COVID-19Infections and infestations | 0/312 | 1/295 | 1/309 | 0/231 | 0/221 | 3/207 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/312 | 0/295 | 3/309 | 0/231 | 0/221 | 3/207 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/312 | 3/295 | 0/309 | 2/231 | 2/221 | 0/207 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/312 | 1/295 | 3/309 | 0/231 | 0/221 | 2/207 |
| Cerebrovascular accidentNervous system disorders | 0/312 | 0/295 | 3/309 | 0/231 | 0/221 | 2/207 |
| Abdominal pain upperGastrointestinal disorders | 2/312 | 0/295 | 1/309 | 0/231 | 0/221 | 2/207 |
| Urinary tract infectionInfections and infestations | 0/312 | 1/295 | 2/309 | 0/231 | 1/221 | 2/207 |
| Event | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | OLE: OCA 10 mg (DB Placebo) | OLE: OCA 10 mg (DB OCA 10 mg) | OLE: Titrated to OCA 25 mg (DB OCA 10 mg Titrated to OCA 25 mg) |
|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 98/312 | 120/295 | 177/309 | 72/231 | 97/221 | 120/207 |
| NauseaGastrointestinal disorders | 43/312 | 32/295 | 48/309 | 19/231 | 28/221 | 39/207 |
| Urinary tract infectionInfections and infestations | 29/312 | 44/295 | 27/309 | 13/231 | 38/221 | 31/207 |
| COVID-19Infections and infestations | 0/312 | 0/295 | 0/309 | 7/231 | 21/221 | 31/207 |
| Abdominal pain upperGastrointestinal disorders | 29/312 | 30/295 | 23/309 | 12/231 | 31/221 | 18/207 |
| Low density lipoprotein increasedInvestigations | 5/312 | 34/295 | 33/309 | 11/231 | 31/221 | 17/207 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 35/312 | 22/295 | 28/309 | 15/231 | 24/221 | 29/207 |
| ConstipationGastrointestinal disorders | 20/312 | 28/295 | 33/309 | 12/231 | 26/221 | 28/207 |
| FatigueGeneral disorders | 35/312 | 27/295 | 36/309 | 15/231 | 27/221 | 27/207 |
| DiarrhoeaGastrointestinal disorders | 38/312 | 28/295 | 22/309 | 12/231 | 24/221 | 20/207 |
Intent-To-Treat (ITT) Population: included all randomized participants.
| Age, Continuous(Years) | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | Total |
|---|---|---|---|---|
| Mean | 59.5 ± 8.99 | 60.1 ± 8.70 | 60.1 ± 8.67 | 59.9 ± 8.78 |
| Sex: Female, Male(Participants) | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | Total |
|---|---|---|---|---|
| Female | 212 | 184 | 209 | 605 |
| Male | 101 | 112 | 101 | 314 |
| Ethnicity (NIH/OMB)(Participants) | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 44 | 52 | 55 | 151 |
| Not Hispanic or Latino | 246 | 217 | 233 | 696 |
| Unknown or Not Reported | 23 | 27 | 22 | 72 |
| Race (NIH/OMB)(Participants) | DB: Placebo | DB: OCA 10 Milligrams (mg) | DB: OCA 10 mg Titrated to OCA 25 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 3 | 4 | 10 |
| Asian | 8 | 5 | 5 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 3 | 4 |
| Black or African American | 4 | 6 | 4 | 14 |
| White | 272 | 254 | 272 | 798 |
| More than one race | 1 | 2 | 1 | 4 |
| Unknown or Not Reported | 25 | 25 | 21 | 71 |
Showing the first 100 of 192 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Sep 2022, 60 months.
Results were first posted in Oct 2023, 1 year 1 month after primary completion.
Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obeticholic acid
Non-alcoholic Fatty Liver Disease →